The acquisition of Attune Medical by Haemonetics is a strategic move to enhance its product portfolio and market presence. The upfront payment of $160M, along with additional contingent consideration based on sales growth, indicates a positive outlook on the synergy between the two companies. This deal is likely to be viewed positively by investors, as it demonstrates Haemonetics' commitment to growth and expansion, potentially leading to an increase in stock price in the short term.